{"ticker": {"uuid": "4dfa9c09-41c9-47e1-b28d-824cd07172c3", "symbol": "RARE", "name": "Ultragenyx", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-raises-price-target-ultragenyx-113826055.html", "source_name": "MT Newswires", "published_at": "2026-07-13T11:38:26+00:00", "published_display": "13 Jul 2026 11:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ultragenyx-releases-2025-impact-report-130800788.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T13:08:00+00:00", "published_display": "08 Jul 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T10:35:19+00:00", "published_display": "08 Jul 2026 10:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-capital-adjusts-ultragenyx-pharmaceutical-115107974.html", "source_name": "MT Newswires", "published_at": "2026-07-07T11:51:07+00:00", "published_display": "07 Jul 2026 11:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVldjR0VNb3VtVU8wS0JXRk45dTZHd3FOVGVGazNRaHlOV0R0SFM0cVpXZE5OYUxFR0FjTG9KMHBlVGhVZ3dZS093RzY0eDVvc1hfNkg4cTZVY2xyc3gtdUZ4VG8wYktFZEhDVGhxYzlUTmIzM2ZzSXFDcmZVSndFVVFDMllYM3RIbko1NnlqSjZSQWtKb0pfeFdNNFNydG5LcmpZRHh4Nldadw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPLUh2UFV6TlA3TnZEamNrZlNOQWgybDdoTTNHTmVwZkFqbGhFWjMyMjlHN3ZKNTRXbjY1MjIzbmxKc0xpNjlNXzc1UnNsVGpfaS1MdTcyTERwTDdjS3Z3ZXNuSzFVdW9sNDdDaFc0LWVkZHZjdkNDVExHcjc2X0xLbWw5ZmxBRUc2MVVBTFpKM2ZOMGZI?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNeWw4am9xNmJjbnlwYlY3RXRfcml2cVA2V29ISmF0Vk1GVE5qVVpzWDl5YlJGNDRkY3ZrVkpTZ1AzTlk4WC05ekx1d2RrRmdWcWR0RE1Id0NNcHRfR0pKRDBqek04eVo2R1kzZFo5RG5aSVdYcWRGT2dsQkczY0pFcDJQc1hJSURianZTRFVfN1FsRm02bXFDT01jWnVQUmNkNk1aXzZqbmVUYjBFUjhXcFM1c0xQdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ultragenyx-reports-inducement-grant-under-203000636.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T20:30:00+00:00", "published_display": "19 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) legal chief sells 1,899 company shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSVNTQ2JrVFl4TjhTRzNqUU44dXFSUjlQZTZfVUJrZ2RwQm4xMG5NT0ZELU52aVpiQkg1MGNIOEhqMWxoV0hIdUs4TUF6WDliUzR6WTRQZGZ3WF9vZjBpTHNib2JrRmMtb0N5cVJzcWxQSEd1UEdsQXFFU0ZhaUs0SnI0UWdPR3hGbzhSVUdZcV91UVBSNkI0dnZjbTV0WG40eFRqaWtXb0YxYXFodmdRbjhiYUM1OGVzZ2FQOFo4Ylg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Ultragenyx Pharmaceutical Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOT09Id2RQRkJRaDZxZS14T0ttUE1vVU9xRlU1bjRwRGZoWERESlM1TlB1dlhtYzNzczllR2hmRy14QmtKOGxaeEw2S0pBUUpORTZSMDVsVGpUXzlSQUQzTW5VZENPT1Nsb3JlRGdVZ09CTTFJc0xuaUx3azFKcXI0SVpJNmk3d2hqYUJ6MjZFN3lnZzk5akkybXZESWJlc19NZ2F3RnBCc0Zvdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RARE (NASDAQ) proposed sale of 2,000 restricted shares by broker-dealer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPU1REb1BTekFwRkxvQ1VlaS1nNFlnc1lXa2laTENkZlN3emoybVAwMnhmWXVIY1VUb2hMV1M3djJNVnprbmNsbzg1SlE2dDRtUHlXeEZYVWpESlgzZXB5bUZHVldLM09sbG12TmFuX1ZLNjRnQThOR3pLM2EwcVMtbUh2b1N5eGRhOFl6TF9kVE5qVWQwQlJjMlJRUHVDaWFETWNQV0ROUF9Tdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) director sells 2,000 shares at $25.05", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQV2hhRzZlTVpwbm9Ea1c5M1llbUgySVZxVU5Id3QzSWpPZFBPRmlyOUxjVUhROFVCUWt0clBtNDJWNGlubHFsT1dFczZ6NzhuTTREZEJtVXY0eXc3Vk9DSzlqTWNIRXRiOXJMVlFCeTNJRnFfd2Z4RFVQbm0xYUo5ZVE4UGVKcWpSbEV5N3NydDN4QXpuUWhUSC1CZzVHUjNXOFlta2g0QVcwazV3Mk9xc2tfTWNYakIzQl9udVRVc1o?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/why-ultragenyx-pharmaceutical-rare-one-152845893.html", "source_name": "Insider Monkey", "published_at": "2026-06-13T15:28:45+00:00", "published_display": "13 Jun 2026 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ultragenyx Pharmaceutical (RARE) Valuation After UX111 FDA Review Acceptance And Growing GTX-102 Optimism", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxQN1VFQnpOa2pKT2VJQ3NsOVhZbS0wZVJsYm9yazB1cmJLRE8xV0t3UmxRckV5MzF4U2dTaUc5SVhMbWhwRFRUTW5HR0xVNHVBdHFrclVTVkkzY2FxNEMzUXYwN2RhWFVIbUw5UkkzWlVWUHk2TFFMakJ1OUJ4NFJfU2lMY3Q0YkZyTkpjTk5lSkdRVDdFRGhZNWhXbUVWMlMzMF9tQUtjZjhlUjhFVGZwcnZKUDFsWlE5SkRHWEE2c25pT1g5WWNHMFJGSmp2WHZYMjhLWHB0SDN5YWlXemdZNEFKdEtYU1AzNnpabDFFUzLSAfYBQVVfeXFMTkZGWjgtVVV0aU5HNWRuaE14Z1RFRDcyZktDeF9zdUQyZnVzcS1CUTBIbUpsUWduT1Y5cGFFMEJkbXBfVmoyNkU1V2hETXJvZXRYc29jekpDRFRodkFpeDhEWFZZMzAyeDJuc19odE9pRDFUVEh3TllLMlRpSV9uZF9FaUVLa3RVSVJBT19EWUhGTERUMHgtRGQtUDJCRWxqRlV0WkVqLW9sZ1VNNWlPQ1pLdTUzNGZGMnQxNER3UHg3TlR6bXFNWWUtOU9JRnVHUzE1U0MtZm9iWkg3SEFxTmw0dEppclEzbnJJMFFFTzlnQ0xBdlRn?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street Views", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ultragenyx-pharmaceutical-rare-investment-story-170621370.html", "source_name": "Simply Wall St.", "published_at": "2026-06-06T17:06:21+00:00", "published_display": "06 Jun 2026 17:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/institutional-confidence-gtx-102-fuels-155550073.html", "source_name": "Insider Monkey", "published_at": "2026-06-05T15:55:50+00:00", "published_display": "05 Jun 2026 15:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) director receives RSU and stock option grants in new Form 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZUdVblBoR0h3N3d6MGJQMEZUOGlGN2hwb19JNGFPNjRxN3hMWGFqNUtwZHBpUFlMUUFYSUpwQjZ5ZjIza2dQYm5XZUdqaTJ5WTFOVjRxdGRxdEExTmwzcFE1VVFKSWF3RThfWTR3cVdqNVd5WTJSYkphMW1JWnpKVXB6Z2pOVV9GeXZFNU9HNGNwU3NtaEZWbmN0ek5hTEg3N1JYc3BSUG1mWWxzaGktcm1sekdXUDROcjlzaEgxSXU?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ultragenyx investors can watch CFO at Bank of America panel May 12", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOc2pSZ2piQjFyNEtyekRIMzVzdGJlWm40OWF5Rl9lLWJMR2lHdU0wajFfTUtjRjlDMHpVamhhYmEyTnFlVkNkSndFN0hKOUpvQS1XYXc0dlNJMTlIbVZPUHJNTUhBQjdPM2syM1VYeDBBZTRjaWJ5UUpaY0JRQ29TX3hZcmZEd1hqc1RxZU92bnpqR1d4NzF2VkVmX3FmU1g2b0ZVenNjb0U4ODhkR0N5RXg0SjNaTXV6?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts (NASDAQ:RARE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQlhRWm0yVWYxQVRVWDFSLUx1Qm53bjRaWnB0T2R2Z094YjkwWWt4UktKdy0xNlZ2QkdaMURZY3ZWenZGb2pVckhHRzgyaXpXOTJDajlJQUxaOThQNGJBNkZlU0lneTYxTkdqQVJIWnlXekVCUk5iVG1aN2phaEU5QmUyOWRkdHdaLURQQ1NvQUx1MjV6ajdzX3JHTmhJaFMtWnNlcWU4aHJ1UGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ultragenyx Pharmaceutical (RARE) Now Attractive After Recent 8.1% Weekly Share Price Jump", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Ultragenyx Pharmaceutical\u2019s Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPQ2hXSWFYTUtwXzFNeVBQU29GeTdTaGItZHZ4MFhJeFo3N2VIVDZwQnRFeGZ6NFNIQ2NzRDdTTV95WUw0SHpneW9iOUNEd2dQUU4tQUx2Yk5nVUtCNHRINi1rMm82dHltaUVfSnJCM0k2NnAya0lFZHRpM3QzN2tSaGt2cVdHS3VzaTJfNzZHRGVaMklaUVdqLTIzOHlLdHNUdW96SmVJakJQY3gzajBLUm1n?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOYmFrcThraXJBR0hYSXUwbC1SWDBsRExzLVhlYnAySWIwd2VDNEczZ1pESnZoYVZjSGdkTWJOYWJITG40Q1h4bF9IR3NNWFY4OTFfcnRWX1o4S2RBM2o5SDlmWHhUZWRJQVQ4R2FlSjVOM1VhYXNmQlExNmx4RU41MzQwRVlfUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZnhqM0ZoVllQZGV5SnlMY2IzUWdSSWZ0RFRTSGpDN2kzNlF4UldSY3lrNEk3dVlsWGx0TTRlcGVCaWtTNV9pdVh6WGx5a19RSzlFUUFVNkw5SE1GNFFMaFRzYTRkUU5nb3FzZHExNTluNGRBWFZGaDBJWWhyVkgyc0w4STNCWnUzdjR2Vg?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOWjlQVmNBbVBsTlNiYzQ5R1dvanUyZjB3ZDZGUjIxWDBnWXBpWGRUbHItakl5eGFUWkpRTW5CVmJGRTZEa0ViSTZJVW5DMlB2VjFGYWxwcG9ZbEEyTjlKOWlTbXQzTHdOLXB0WFBLMFVXN0p6QllFdjhvVVlBdHhKRW9RSW5YbFU5djM3UjF0VTh4dEc4U2k3cmhKYWNmdnVyby1XclF4TGVEaV9Sci1HX2UwN3ljQkE0OWpuLWJwYlUwWVNYTGFz?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-01-04T08:00:00+00:00", "published_display": "04 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOWExuVlhCRVliVlkya18xRkVTbEk3amJnNEJPMkNjcEJSTlVmOUg3dlQ4QUVMdV9UcVQ2SDdEY2l0eDVjYUNSTERheURlWlI3bFVmaksyZFB0LUVYRzVJWlg2V25ydzcxU2ttc0dWQTR2aEJWaEpqc3VOd3o1eHlwNTdObk92Nkp3Q3FId1g4V3RPbzEzbWI4WA?oc=5", "source_name": "The Motley Fool", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ultragenyx Pharmaceutical (NASDAQ:RARE) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SEC Filing\u2014Ultragenyx Pharmaceutical Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE5zQkZHc2lNVExlRjFaUFhTTTFyYVIyZDNWUDNfQ0JPaWpqUDdrb3gzaHBxY0tnNkgyNkxFLTl5VzJWOTMtWmNqaGo5UHI4bWkxbFE?oc=5", "source_name": "Ultragenyx", "published_at": "2020-07-11T14:38:49+00:00", "published_display": "11 Jul 2020 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-raises-price-target-ultragenyx-113826055.html", "source_name": "MT Newswires", "published_at": "2026-07-13T11:38:26+00:00", "published_display": "13 Jul 2026 11:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ultragenyx-releases-2025-impact-report-130800788.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T13:08:00+00:00", "published_display": "08 Jul 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T10:35:19+00:00", "published_display": "08 Jul 2026 10:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/rbc-capital-adjusts-ultragenyx-pharmaceutical-115107974.html", "source_name": "MT Newswires", "published_at": "2026-07-07T11:51:07+00:00", "published_display": "07 Jul 2026 11:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVldjR0VNb3VtVU8wS0JXRk45dTZHd3FOVGVGazNRaHlOV0R0SFM0cVpXZE5OYUxFR0FjTG9KMHBlVGhVZ3dZS093RzY0eDVvc1hfNkg4cTZVY2xyc3gtdUZ4VG8wYktFZEhDVGhxYzlUTmIzM2ZzSXFDcmZVSndFVVFDMllYM3RIbko1NnlqSjZSQWtKb0pfeFdNNFNydG5LcmpZRHh4Nldadw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPLUh2UFV6TlA3TnZEamNrZlNOQWgybDdoTTNHTmVwZkFqbGhFWjMyMjlHN3ZKNTRXbjY1MjIzbmxKc0xpNjlNXzc1UnNsVGpfaS1MdTcyTERwTDdjS3Z3ZXNuSzFVdW9sNDdDaFc0LWVkZHZjdkNDVExHcjc2X0xLbWw5ZmxBRUc2MVVBTFpKM2ZOMGZI?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNeWw4am9xNmJjbnlwYlY3RXRfcml2cVA2V29ISmF0Vk1GVE5qVVpzWDl5YlJGNDRkY3ZrVkpTZ1AzTlk4WC05ekx1d2RrRmdWcWR0RE1Id0NNcHRfR0pKRDBqek04eVo2R1kzZFo5RG5aSVdYcWRGT2dsQkczY0pFcDJQc1hJSURianZTRFVfN1FsRm02bXFDT01jWnVQUmNkNk1aXzZqbmVUYjBFUjhXcFM1c0xQdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ultragenyx-reports-inducement-grant-under-203000636.html", "source_name": "GlobeNewswire", "published_at": "2026-06-19T20:30:00+00:00", "published_display": "19 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) legal chief sells 1,899 company shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQSVNTQ2JrVFl4TjhTRzNqUU44dXFSUjlQZTZfVUJrZ2RwQm4xMG5NT0ZELU52aVpiQkg1MGNIOEhqMWxoV0hIdUs4TUF6WDliUzR6WTRQZGZ3WF9vZjBpTHNib2JrRmMtb0N5cVJzcWxQSEd1UEdsQXFFU0ZhaUs0SnI0UWdPR3hGbzhSVUdZcV91UVBSNkI0dnZjbTV0WG40eFRqaWtXb0YxYXFodmdRbjhiYUM1OGVzZ2FQOFo4Ylg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Ultragenyx Pharmaceutical Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOT09Id2RQRkJRaDZxZS14T0ttUE1vVU9xRlU1bjRwRGZoWERESlM1TlB1dlhtYzNzczllR2hmRy14QmtKOGxaeEw2S0pBUUpORTZSMDVsVGpUXzlSQUQzTW5VZENPT1Nsb3JlRGdVZ09CTTFJc0xuaUx3azFKcXI0SVpJNmk3d2hqYUJ6MjZFN3lnZzk5akkybXZESWJlc19NZ2F3RnBCc0Zvdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RARE (NASDAQ) proposed sale of 2,000 restricted shares by broker-dealer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPU1REb1BTekFwRkxvQ1VlaS1nNFlnc1lXa2laTENkZlN3emoybVAwMnhmWXVIY1VUb2hMV1M3djJNVnprbmNsbzg1SlE2dDRtUHlXeEZYVWpESlgzZXB5bUZHVldLM09sbG12TmFuX1ZLNjRnQThOR3pLM2EwcVMtbUh2b1N5eGRhOFl6TF9kVE5qVWQwQlJjMlJRUHVDaWFETWNQV0ROUF9Tdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) director sells 2,000 shares at $25.05", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQV2hhRzZlTVpwbm9Ea1c5M1llbUgySVZxVU5Id3QzSWpPZFBPRmlyOUxjVUhROFVCUWt0clBtNDJWNGlubHFsT1dFczZ6NzhuTTREZEJtVXY0eXc3Vk9DSzlqTWNIRXRiOXJMVlFCeTNJRnFfd2Z4RFVQbm0xYUo5ZVE4UGVKcWpSbEV5N3NydDN4QXpuUWhUSC1CZzVHUjNXOFlta2g0QVcwazV3Mk9xc2tfTWNYakIzQl9udVRVc1o?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Ultragenyx Pharmaceutical (RARE) is One of the Best Buy-the-Dip Stocks", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/why-ultragenyx-pharmaceutical-rare-one-152845893.html", "source_name": "Insider Monkey", "published_at": "2026-06-13T15:28:45+00:00", "published_display": "13 Jun 2026 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ultragenyx Pharmaceutical (RARE) Valuation After UX111 FDA Review Acceptance And Growing GTX-102 Optimism", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Ultragenyx Pharmaceutical (RARE) Investment Story Is Shifting With New Data And Street Views", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ultragenyx-pharmaceutical-rare-investment-story-170621370.html", "source_name": "Simply Wall St.", "published_at": "2026-06-06T17:06:21+00:00", "published_display": "06 Jun 2026 17:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/institutional-confidence-gtx-102-fuels-155550073.html", "source_name": "Insider Monkey", "published_at": "2026-06-05T15:55:50+00:00", "published_display": "05 Jun 2026 15:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx (RARE) director receives RSU and stock option grants in new Form 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZUdVblBoR0h3N3d6MGJQMEZUOGlGN2hwb19JNGFPNjRxN3hMWGFqNUtwZHBpUFlMUUFYSUpwQjZ5ZjIza2dQYm5XZUdqaTJ5WTFOVjRxdGRxdEExTmwzcFE1VVFKSWF3RThfWTR3cVdqNVd5WTJSYkphMW1JWnpKVXB6Z2pOVV9GeXZFNU9HNGNwU3NtaEZWbmN0ek5hTEg3N1JYc3BSUG1mWWxzaGktcm1sekdXUDROcjlzaEgxSXU?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx investors can watch CFO at Bank of America panel May 12", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOc2pSZ2piQjFyNEtyekRIMzVzdGJlWm40OWF5Rl9lLWJMR2lHdU0wajFfTUtjRjlDMHpVamhhYmEyTnFlVkNkSndFN0hKOUpvQS1XYXc0dlNJMTlIbVZPUHJNTUhBQjdPM2syM1VYeDBBZTRjaWJ5UUpaY0JRQ29TX3hZcmZEd1hqc1RxZU92bnpqR1d4NzF2VkVmX3FmU1g2b0ZVenNjb0U4ODhkR0N5RXg0SjNaTXV6?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts (NASDAQ:RARE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPQlhRWm0yVWYxQVRVWDFSLUx1Qm53bjRaWnB0T2R2Z094YjkwWWt4UktKdy0xNlZ2QkdaMURZY3ZWenZGb2pVckhHRzgyaXpXOTJDajlJQUxaOThQNGJBNkZlU0lneTYxTkdqQVJIWnlXekVCUk5iVG1aN2phaEU5QmUyOWRkdHdaLURQQ1NvQUx1MjV6ajdzX3JHTmhJaFMtWnNlcWU4aHJ1UGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ultragenyx Pharmaceutical (RARE) Now Attractive After Recent 8.1% Weekly Share Price Jump", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPSHUxRHpiajVQVlhLaXh1SEhQdHFjYjhXSmVZTmJWbm9uRlFKUjk3enp2c0kxeTZyX2Fjc1ZHR09MVmZnenkxMDdBUjJLZVZtbHF0c1pXQTNkVldPd29QdFBtbG9YTTFQODZmX2JVemJtUVlDNjNNcFZGc0dKYnRCWVBtckRIOE1CWGdKbkE2Mm5laFM0R1pZN3hPMGZDNjdMMC1KSks4dTNuRkY4Z0xENjBrdnZaeUZiNmRNbWEtNC03aW1WOF9hc2F5eVZwemN1RmpjMjBrRXVwbmlzek9uVURzc0ZWQVVKT1k2ZnRSVWfSAfYBQVVfeXFMTmgzMG9PWEk0dmNSblYzUVhCSnFKT2ZaUlRCS1FheGpvdEVDY21OQnlaRjNpZUF2dEIyS0JfZEtBSFRjeV9CbmIyNXBIVVdTMzNhN3BTRXBHM0tQaE1LR05Vc21WSWxlT01EOWpNdzF5ZEg3eXl5aTl5MWQzUElaRWJkbXAtRkhKMkFzWjE1SGpXbHFWcmpsR2lMczNXWXpDN0l4dlBkTzhZR2UyQV9nOTdoamlUY1NES1FNV0MwTmVXZ0ZzRFdtNnFoLWJtU0FQRmpzQkJzazNKZlJocDltWmN2clBackl1a1ZRM29hNDlIQlp1UnFB?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Ultragenyx Pharmaceutical\u2019s Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPQ2hXSWFYTUtwXzFNeVBQU29GeTdTaGItZHZ4MFhJeFo3N2VIVDZwQnRFeGZ6NFNIQ2NzRDdTTV95WUw0SHpneW9iOUNEd2dQUU4tQUx2Yk5nVUtCNHRINi1rMm82dHltaUVfSnJCM0k2NnAya0lFZHRpM3QzN2tSaGt2cVdHS3VzaTJfNzZHRGVaMklaUVdqLTIzOHlLdHNUdW96SmVJakJQY3gzajBLUm1n?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOYmFrcThraXJBR0hYSXUwbC1SWDBsRExzLVhlYnAySWIwd2VDNEczZ1pESnZoYVZjSGdkTWJOYWJITG40Q1h4bF9IR3NNWFY4OTFfcnRWX1o4S2RBM2o5SDlmWHhUZWRJQVQ4R2FlSjVOM1VhYXNmQlExNmx4RU41MzQwRVlfUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZnhqM0ZoVllQZGV5SnlMY2IzUWdSSWZ0RFRTSGpDN2kzNlF4UldSY3lrNEk3dVlsWGx0TTRlcGVCaWtTNV9pdVh6WGx5a19RSzlFUUFVNkw5SE1GNFFMaFRzYTRkUU5nb3FzZHExNTluNGRBWFZGaDBJWWhyVkgyc0w4STNCWnUzdjR2Vg?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOWjlQVmNBbVBsTlNiYzQ5R1dvanUyZjB3ZDZGUjIxWDBnWXBpWGRUbHItakl5eGFUWkpRTW5CVmJGRTZEa0ViSTZJVW5DMlB2VjFGYWxwcG9ZbEEyTjlKOWlTbXQzTHdOLXB0WFBLMFVXN0p6QllFdjhvVVlBdHhKRW9RSW5YbFU5djM3UjF0VTh4dEc4U2k3cmhKYWNmdnVyby1XclF4TGVEaV9Sci1HX2UwN3ljQkE0OWpuLWJwYlUwWVNYTGFz?oc=5", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-01-04T08:00:00+00:00", "published_display": "04 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOWExuVlhCRVliVlkya18xRkVTbEk3amJnNEJPMkNjcEJSTlVmOUg3dlQ4QUVMdV9UcVQ2SDdEY2l0eDVjYUNSTERheURlWlI3bFVmaksyZFB0LUVYRzVJWlg2V25ydzcxU2ttc0dWQTR2aEJWaEpqc3VOd3o1eHlwNTdObk92Nkp3Q3FId1g4V3RPbzEzbWI4WA?oc=5", "source_name": "The Motley Fool", "published_at": "2025-12-29T08:00:00+00:00", "published_display": "29 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ultragenyx Pharmaceutical (NASDAQ:RARE) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-28T07:00:00+00:00", "published_display": "28 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SEC Filing\u2014Ultragenyx Pharmaceutical Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE5zQkZHc2lNVExlRjFaUFhTTTFyYVIyZDNWUDNfQ0JPaWpqUDdrb3gzaHBxY0tnNkgyNkxFLTl5VzJWOTMtWmNqaGo5UHI4bWkxbFE?oc=5", "source_name": "Ultragenyx", "published_at": "2020-07-11T14:38:49+00:00", "published_display": "11 Jul 2020 14:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 35, "sentiment_summary": {"positive": 4, "negative": 2, "neutral": 29, "score": 51, "total": 35, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 13.35, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 4, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 33.82, "latest_week": "2026-07-10", "one_week_move": 1.0, "four_week_move": 38.9, "twelve_week_move": 36.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.448766, "market_dynamics_buy_signal": false, "relative_strength": 4.822927, "fair_value_gap": -10.9, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 51.4555, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.0% over one week, +38.9% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 6}, {"label": "MT Newswires", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "Insider Monkey", "count": 2}, {"label": "Simply Wall St.", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 27}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "27", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.0% over one week, +38.9% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating"}], "updated_at": "2026-07-16T11:43:26.264599+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}